The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts
Open accessAbstract
Viral replication usually requires that innate intracellular lines of defence be overcome, a task usually accomplished by specialized viral gene products. The virion infectivity factor (Vif) protein of human immunodeficiency virus (HIV) is required during the late stages of viral production to counter the antiviral activity of APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G; also known as CEM15), a protein expressed notably in human T lymphocytes. When produced in the presence of APOBEC3G, vif-defective virus is non-infectious. APOBEC3G is closely related to APOBEC1, the central component of an RNA-editing complex that deaminates a cytosine residue in apoB messenger RNA. APOBEC family members also have potent DNA mutator activity through dC deamination; however, whether the editing potential of APOBEC3G has any relevance to HIV inhibition is unknown. Here, we demonstrate that it does, as APOBEC3G exerts its antiviral effect during reverse transcription to trigger G-to-A hypermutation in the nascent retroviral DNA. We also find that APOBEC3G can act on a broad range of retroviruses in addition to HIV, suggesting that hypermutation by editing is a general innate defence mechanism against this important group of pathogens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, cellular RNA polymerase II, along with various viral and host factors, also influences retroviral mutations, particularly in HIV-1 (O’Neil et al. 2002, Mangeat et al. 2003, Chiu and Greene 2006, Hughes 2015).”
From Beyond reverse transcription: molecular mechanisms and emerging paradigms in retroviral replication (2026) · cites this paper as Mangeat et al. 2003
Citations
Cites
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein
Sheehy, A. M., Gaddis, N., Choi, J. D., & Malim, M. H. (2002) · Nature · doi:10.1038/nature00939 · Cited by 2,407
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977
Self-citationA novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine
Powell, L. M., Wallis, S. C., Pease, R. J., Edwards, Y. H., Knott, T. J., & Scott, J. (1987) · Cell · doi:10.1016/0092-8674(87)90510-1 · Cited by 1,039
Transcription-targeted DNA deamination by the AID antibody diversification enzyme
Chaudhuri, J., Tian, M., Khuong, C., Chua, K. F., Pinaud, E., & Alt, F. W. (2003) · Nature · doi:10.1038/nature01574 · Cited by 746
An Anthropoid-Specific Locus of Orphan C to U RNA-Editing Enzymes on Chromosome 22
Jarmuz, A., Chester, A., Bayliss, J., Gisbourne, J., Dunham, I., Scott, J., & Navaratnam, N. (2002) · Genomics · doi:10.1006/geno.2002.6718 · Cited by 711
A quantitative assay for HIV DNA integration in vivo
Butler, S. L., Hansen, M. S., & Bushman, F. D. (2001) · Nature Medicine · doi:10.1038/87979 · Cited by 695
RNA Editing Enzyme APOBEC1 and Some of Its Homologs Can Act as DNA Mutators
Harris, R. S., Petersen‐Mahrt, S. K., & Neuberger, M. S. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00742-6 · Cited by 609
Molecular Cloning of an Apolipoprotein B Messenger RNA Editing Protein
Teng, B., Burant, C. F., & Davidson, N. O. (1993) · Science · doi:10.1126/science.8511591 · Cited by 536
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes
Gabuzda, D. H., Lawrence, K., Langhoff, E., Terwilliger, E., Dorfman, T., Haseltine, W. A., & Sodroski, J. (1992) · Journal of Virology · doi:10.1128/jvi.66.11.6489-6495.1992 · Cited by 444
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells
von Schwedler, U. K., Song, J., Aiken, C., & Trono, D. (1993) · Journal of Virology · doi:10.1128/jvi.67.8.4945-4955.1993 · Cited by 441
Self-citation
Cited by
Sorted by citations
Rates of evolutionary change in viruses: patterns and determinants
Duffy, S., Shackelton, L. A., & Holmes, E. C. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2323 · Cited by 1,605
Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex
Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., & Yu, X.-F. (2003) · Science · doi:10.1126/science.1089591 · Cited by 1,194
Type I Interferons in Host Defense
Stetson, D. B., & Medzhitov, R. M. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.007 · Cited by 1,225
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif
Sheehy, A. M., Gaddis, N., & Malim, M. H. (2003) · Nature Medicine · doi:10.1038/nm945 · Cited by 961
Sanjuán, R., & Domingo‐Calap, P. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2299-6 · Cited by 995
Metadata
- Authors
- Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., & Trono, D.
- Affiliations
- University of Geneva (CH)
- Corresponding author
- Trono, Didier
- Venue
- Nature
- Published
- 2003-05-28
- Volume
- 424
- Issue
- 6944
- Pages
- 99-103
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1966343819
- Cited by
- 1,486
- References
- 28
- Citations by year
- 2026: 20 · 2025: 29 · 2024: 23 · 2023: 28 · 2022: 25 · 2021: 43 · 2020: 37 · 2019: 53 · 2018: 49 · 2017: 56 · 2016: 58 · 2015: 58 · 2014: 79 · 2013: 87 · 2012: 97
- FWCI
- 36.98
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Keywords
- APOBEC3G, HIV-1 Vif, APOBEC1, cytosine deamination, reverse transcription, G-to-A hypermutation, retrovirus restriction, T cells, RNA editing
- MeSH terms
- APOBEC-3G Deaminase, Antiviral Agents, Base Sequence, Cell Line, Cytidine Deaminase, DNA, Viral, Humans, Molecular Sequence Data, Nucleoside Deaminases, Proteins, Repressor Proteins, RNA, Messenger, Transcription, Genetic, Virus Replication, HIV-1, Mutagenesis, Gene Products, vif, Point Mutation, RNA Editing, Viral Load, vif Gene Products, Human Immunodeficiency Virus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
